IBC's 23rd Annual Antibody Engineering, 10th Annual Antibody Therapeutics international conferences and the 2012 Annual Meeting of The Antibody Society: December 3-6, 2012, San Diego, CA.

MAbs · 2013 · PMC3893229 · PMID 23575266

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

CDA1 alone showed a trend toward delay in recurrence in a Phase 2 trial, and together with MDX-1388 reduced recurrence rates but did not affect the duration and severity of diarrhea.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.